


A phase 2 study of Nectin-4-targeting Bicycle<sup>®</sup> Drug Conjugate zelenectide pevedotin (BT8009) in patients with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer (NSCLC)

#### Not yet recruiting



Contact clinicalstudies@bicycletx.com to enroll patients and learn more.



See eligibility criteria on reverse side.

Primary endpoint: ORR



NECTIN4-amplified advanced or metastatic non-small cell lung cancer (NSCLC)

## Are your patients eligible?

### Key eligibility criteria

Inclusion

At the most recent data cutoff from Duravelo-1, zelenectide pevedotin demonstrated a tolerable safety profile and preliminary antitumor activity in *NECTIN4*-amplified lung cancer.<sup>1-3</sup>

#### Exclusion

$\bigcirc$	Histologically or cytologically confirmed advanced or metastatic NSCLC
$\bigcirc$	Confirmed NECTIN4 gene amplification
$\bigcirc$	No more than 3 prior lines of systemic therapy in the advanced/ metastatic setting
$\bigcirc$	Participants with no known actionable genomic alterations must have received both platinum-based therapy and immunotherapy (sequentially or in combination)
$\bigcirc$	Participants with known actionable genomic alterations are eligible provided they have received or are not candidates for standard targeted therapy in the advanced/metastatic setting

Adequate archival or fresh tumor tissue comprised of advanced or metastatic NSCLC

Measurable disease as defined by RECIST v1.1

- ✓ Life expectancy ≥12 weeks
- ✓ ECOG PS ≤1

## COHORT A

Histologically or cytologically confirmed nonsquamous NSCLC

## COHORT B

Histologically or cytologically confirmed squamous NSCLC

× Mixed small cell lung cancer (SCLC) and NSCLC histology

- × Active or untreated CNS metastases
- × Prior treatment with any MMAE-based therapy
- Prior treatment with any systemic anticancer therapy within 28 days (or 5 half-lives)
- Ongoing Grade ≥2 toxicity associated with prior treatment (with the exception of well-controlled immuno-oncology related endocrine disorders on supportive or replacement therapy, and alopecia)
- V Uncontrolled pleural or pericardial effusion or ascites requiring recurrent draining procedures
- Active ILD or pneumonitis requiring ongoing treatment or any prior history of ILD or noninfectious pneumonitis requiring high-dose glucocorticoids

# Contact clinicalstudies@bicycletx.com to enroll patients and learn more.



Product candidates are investigational only and are not approved medicines.

CNS=central nervous system; ECOG PS=Eastern Cooperative Oncology Group Performance Status; ILD=interstitial lung disease; MMAE=monomethyl auristatin E; RECIST=Response Evaluation Criteria in Solid Tumors.

**References: 1.** Baldini C, et al. Presented at: 2023 American Society of Clinical Oncology (ASCO) Annual Meeting; June 2-6, 2023; Chicago, IL. Abstract 498. **2.** Bader J, et al. Presented at: 2024 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31-June 4, 2024; Chicago, IL. Abstract 3088. **3.** Verlingue L, et al. Presented at 2025 European Lung Cancer Congress; March 26-29, 2025; Paris, France. Abstract 96P.